EP1436325A1 - Microfluidized leishmania antigen and methods of making and using thereof - Google Patents
Microfluidized leishmania antigen and methods of making and using thereofInfo
- Publication number
- EP1436325A1 EP1436325A1 EP01979743A EP01979743A EP1436325A1 EP 1436325 A1 EP1436325 A1 EP 1436325A1 EP 01979743 A EP01979743 A EP 01979743A EP 01979743 A EP01979743 A EP 01979743A EP 1436325 A1 EP1436325 A1 EP 1436325A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- subject
- microfluidized
- lysate preparation
- leishmaniasis
- microfluidized lysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000222722 Leishmania <genus> Species 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 48
- 239000000427 antigen Substances 0.000 title claims abstract description 42
- 102000036639 antigens Human genes 0.000 title claims abstract description 42
- 108091007433 antigens Proteins 0.000 title claims abstract description 42
- 239000006166 lysate Substances 0.000 claims abstract description 118
- 238000002360 preparation method Methods 0.000 claims abstract description 111
- 244000045947 parasite Species 0.000 claims abstract description 58
- 238000012360 testing method Methods 0.000 claims abstract description 44
- 238000003556 assay Methods 0.000 claims abstract description 19
- 208000004554 Leishmaniasis Diseases 0.000 claims description 35
- 206010047505 Visceral leishmaniasis Diseases 0.000 claims description 30
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 claims description 30
- 230000000890 antigenic effect Effects 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 241000222696 Leishmania guyanensis Species 0.000 claims description 16
- 241001009234 Sciopsyche tropica Species 0.000 claims description 13
- 230000009851 immunogenic response Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 240000005528 Arctium lappa Species 0.000 claims description 10
- 241000222724 Leishmania amazonensis Species 0.000 claims description 10
- 241000222740 Leishmania braziliensis Species 0.000 claims description 10
- 241000178949 Leishmania chagasi Species 0.000 claims description 10
- 241000222727 Leishmania donovani Species 0.000 claims description 10
- 241000222697 Leishmania infantum Species 0.000 claims description 10
- 241000222695 Leishmania panamensis Species 0.000 claims description 10
- 241000222705 Leishmania pifanoi Species 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241000191796 Calyptosphaeria tropica Species 0.000 claims description 8
- 206010011668 Cutaneous leishmaniasis Diseases 0.000 claims description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
- 241001041685 Eragrostis aethiopica Species 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000520 diphenhydramine Drugs 0.000 claims description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 4
- 210000000245 forearm Anatomy 0.000 claims description 4
- 229960000890 hydrocortisone Drugs 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 2
- 206010024769 Local reaction Diseases 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 241000222704 Leishmania peruviana Species 0.000 claims 4
- 244000020186 Nymphaea lutea Species 0.000 claims 4
- 238000011018 current good manufacturing practice Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 20
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000000509 infertility Diseases 0.000 description 11
- 230000036512 infertility Effects 0.000 description 11
- 208000021267 infertility disease Diseases 0.000 description 11
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 11
- 241000222734 Leishmania mexicana Species 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 8
- 238000005336 cracking Methods 0.000 description 8
- 230000005951 type IV hypersensitivity Effects 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 244000294000 Ludwigia peruviana Species 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001235 sensitizing effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000225044 Roeboexodon guyanensis Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000035850 clinical syndrome Diseases 0.000 description 3
- -1 coatings Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241000222738 Leishmania aethiopica Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012595 freezing medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100458361 Drosophila melanogaster SmydA-8 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 241000725176 Leishmania RNA virus 1 - 4 Species 0.000 description 1
- 206010057168 Leishmania infections Diseases 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000209152 Zea mays subsp. mexicana Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002514 anti-leishmanial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011997 immunoflourescence assay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates generally to microfluidized Leishmania lysate preparations.
- the present invention relates to microfluidized Leishmania lysate preparations for assays and immunogenic compositions.
- Serology, primary ELISA, IFA and agglutination assays are somewhat useful in the diagnosis of visceral leishmaniasis. Nevertheless, these assays are of little use for diagnosing cutaneous and mucocutaneous leishmaniasis where the antibody liters are low. As a result, the prevention of leishmanial epidemics is greatly hindered and patient management is difficult.
- the strengths of the leishmanin tests include delayed hypersensitivity as an important feature of all forms of leishmaniasis that maybe measured and that the parasitic antigens elicit a cutaneous delayed-type hypersensitivity response in most individuals with cutaneous leishmaniasis, mucocutaneous leishmaniasis, post kala-azar dermal leishmaniasis, and cured visceral leishmaniasis.
- the shortcomings of the leishmanin tests include false positive reactions that can be high in areas where there is a background of leishmaniasis, as many individuals in the healthy populations of endemic leishmaniasis areas having no evidence of past infection may show high rates of leishmanin sensitivity.
- the shortcomings also include cross-reactions with cases of glandular tuberculosis and lepromatous leprosy, cross-reactivity between Leishmania strains as heterologous antigens often give smaller reactions, lack of a universal and standardized Leishmania skin test antigen, unknown sensitizing capacity, unknown stability, unknown dose/response relationships between antigen content and clinical syndrome or infecting parasite, and the standard of care of using Leishmania skin test antigen in many endemic countries is not approved by drug approval agencies such as the U.S. Food and Drug Administration.
- the present invention generally relates to microfluidized leishmanial antigens and methods of making and using thereof. [12] In some embodiments, the present invention relates to a method of preparing a microfluidized lysate preparation comprising microfluidizing a slurry of at least one
- the Leishmania parasite through a chamber and disrupting the leishmania parasite with a sudden release of pressure.
- the method further comprises heat treating the microfluidized lysate preparation.
- the Leishmania parasite may be E. tropica, L. mexicana, L. guyanensis, L. braziliensis, L. major, L. donovani, L. chagasi, L. amazonensis, L. peruviana, L. panamensis, L. pifanoi, L. infantum, orE aethiopica.
- the present invention relates to a microfluidized lysate preparation made by microfluidizing a slurry of at least one Leishmania parasite through a chamber and disrupting the leishmania parasite with a sudden release of pressure and heat treating the microfluidized lysate preparation.
- the Leishmania parasite may be E. tropica, L. mexicana, L. guyanensis, L. braziliensis, L. major, L. donovani, L. chagasi, L. amazonensis, L. peruviana, L. panamensis, L. pifanoi, L. infantum, or L. aethiopica.
- the present invention relates to a skin test antigen assay for detecting whether a subject has been exposed to a Leishmania parasite or was afflicted with Leishmaniasis comprising administering to the subject an antigenic amount of at least one microfluidized lysate preparation of the present invention and observing any immunogenic response to the microfluidized lysate preparation.
- the Leishmania parasite may be E. tropica, L. mexicana, L. guyanensis, L. braziliensis, L. major, L. donovani, L. chagasi, L. amazonensis, L. peruviana, L. panamensis, L. pifanoi, L. infantum, or E.
- an immunogenic response indicates that the subject has been exposed to a Leishmania parasite or was afflicted with Leishmaniasis.
- an induration of about 5 mm or greater observed indicates that the subject has been exposed to a Leishmania parasite or was afflicted with Leishmaniasis.
- the antigenic amount of the microfluidized lysate preparation comprises about 5 ⁇ g to about 30 ⁇ g of total protein.
- the microfluidized lysate preparation is administered intradermally to the volar surface of the forearm of the subject.
- the present invention relates to a kit comprising the microfluidized lysate preparation of the present invention and directions for determining whether a subject has been exposed to a Leishmania parasite or was afflicted with Leishmaniasis.
- the Leishmania parasite may be E. tropica, L. mexicana, L. guyanensis, L. braziliensis, L. major, L. donovani, L. chagasi, L. amazonensis, L. peruviana, L. panamensis, L. pifanoi, L. infantum, or E. aethiopica.
- the kit may further comprise at least one pharmaceutical for treating systemic anaphylaxis such as epinephrine, diphenhydramine, and methyl prednisolone.
- the kit may further comprise at least one pharmaceutical for treating local reactions to the microfluidized lysate preparation such as hydrocortisone, hydrocortisone cream, acetaminophen, or diphenhydramine.
- the present invention relates to antibodies raised against the microfluidized lysate preparation of the present invention.
- the present invention relates to a method of determining whether a subject has been exposed to a given Leishmania parasite comprising administering to the subject a panel of antigenic compositions comprising a plurality of microfluidized lysate preparations prepared from a plurality of Leishmania parasites and detecting a presence of an immunogenic reaction that is characteristic to exposure to the given Leishmania parasite.
- the plurality o ⁇ Leishmania parasites may include at least one parasite belonging to the group consisting of L. tropica, L. mexicana, L. guyanensis, L. braziliensis, L. major, L. donovani, L. chagasi, L. amazonensis, L. peruviana, L. panamensis, L. pifanoi, L. infantum, and E. aethiopica.
- the present invention relates to a method of immunizing a subject against Leishmaniasis comprising administering to the subject an immunogenic amount of the microfluidized lysate preparation.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the microfluidized lysate preparation and a pharmaceutically acceptable stabilizer such as phenol.
- the pharmaceutical composition is in the form of a liquid which may be frozen or freeze-dried.
- the present invention relates to a method for determining post infection of cutaneous leishmaniasis, mucocutaneous leishmaniasis, or post-kala-azar dermal leishmaniasis in a subject comprising administering to the subject an antigenic amount of at least one microfluidized lysate preparation and observing any immunogenic response to the microfluidized lysate preparation.
- the present invention relates to a method for epidemiologically diagnosing cutaneous leishmaniasis, mucocutaneous leishmaniasis, or post-kala-azar dermal leishmaniasis in a subject comprising administering to the subject an antigenic amount of at least one microfluidized lysate preparation and observing any immunogenic response to the microfluidized lysate preparation.
- the present invention relates to a method for determining the pattern of present and past leishmaniasis in a- subject comprising administering to the subject an antigenic amount of at least one microfluidized lysate preparation and observing any immunogenic response to the microfluidized lysate preparation.
- Figure 1 is a flow diagram showing the process for making a Leishmaniasis microfluidized lysate according to the present invention.
- the present invention allows the detection of post infections and epidemiological diagnosis of all forms of leishmaniasis.
- the present invention may be used for screening of individuals such as U.S. Service Members who may have been exposed to Leishmania parasites after deployment to Leishmaniasis endemic areas.
- the present invention may be used in the clinical diagnosis of cutaneous leishmaniasis, mucocutaneous leishmaniasis, and post-kala-azar dermal leishmaniasis in subjects such as U.S. Service Members.
- the present invention may be used to determine the pattern of past and present infections of leishmaniasis.
- the present invention provides microfluidized lysate preparations comprising at least one antigen from at least one Leishmania parasite and methods of making and using thereof.
- the microfluidized lysate preparations of the present invention may be used to elicit induration that is consistent with delayed type hypersensitivity (DTH) in an individual previously infected with or exposed to at least one Leishmania parasite.
- DTH delayed type hypersensitivity
- the microfluidized lysate preparation is injected intradermally.
- the present invention also provides a skin test assay for detecting whether a subject has been exposed to a Leishmania parasite or is or has been afflicted with Leishmaniasis comprising at least one microfluidized lysate preparation of at least one Leishmania parasite.
- the microfluidized lysate of the present invention comprises at least one solubilized antigen of at least one Leishmania parasite.
- the microfluidized lysate preparation may further comprise a mixture of amino acids, lipids, and carbohydrates.
- the Leishmania parasite may be specifically selected for a particular reason. For example, an Old World parasite, such as E. tropica strain WR1063, may be used in order to detect E.
- Leishmania parasites acquired in Southwest Asia.
- any Leishmania parasite, Old World or New World may be selected by one of ordinary skill in the art, prepared, and used according to the present invention.
- Examples of a few Leishmania parasites include L. tropica, L. mexicana, L. guyanensis, L. braziliensis, L. major, L. donovani, L. chagasi, L. amazonensis, L. peruviana, L. panamensis, L. pifanoi, L. infantum, L. aethiopica.
- the L. tropica strain WR1063 used herein was cloned by mechanical-single cell isolation and given the designation, CL1.
- the microfluidized lysate preparations of the present invention were prepared under current good manufacturing practices (cGMP). Disruption of the promatigotes was accomplished by microfluidization comprising passing a parasite slurry through a chamber and disrupting the cells by the sudden release of pressure. Not only does microfluidization allow the release of membrane embedded antigens, but it provides a reproducible method for providing large volumes of preparations.
- the microfluidized lysate preparations were heat-treated at about 95 °C in a water bath for about 30 minutes to deactivate the proteolytic enzymes.
- a strain of vicerotropic leishmania WR1063 was isolated, cloned, and then characterized as L. tropica by isoenzyme analysis.
- Other Leishmania parasites may be used such as L. mexicana as described in Example 2.
- a master seed lot and a production ⁇ seed lot of the clone were used to initiate individual bulk production lots of promastigotes.
- Three bulk lots (about 1 x 10 11 promastigotes each) were pooled in a vial and immediately placed on dry ice. The pooled promastigotes were then thawed by placing the vial in a water bath at about 56 ⁇ 2 °C.
- the vial was placed at about 4 ⁇ 2 °C to cool. After cooling, the contents of the vial were transferred to a pre-tared 250 ml sterile centrifuge bottle on ice using a 10 cc sterile syringe. Two 0.5 ml samples of the suspended cells were pipetted and placed in a sterile 1.5 ml Nunc cryovial (Fisher Scientific, Pittsburgh, PA) and stored at about -80 ⁇ 10 °C. [31] A micro fluidizer, Model #M-110S was used to extract the E. tropica soluble proteins. The regulator was set and wet ice was put into the cooling jacket of the microfluidizer.
- the pump was primed by placing the inlet tubing into 500 ml of 0.001 % Tween 80 and 0.9% saline and then opening the air valve. With the regulator at about 100 ⁇ 5 psi, the inlet tubing was inserted into the promastigotes suspension and run through the microfluidizer. Because the cracking pressure fluctuates, an average reading was taken. Cracked cells were collected into the reservoir containing the uncracked cells and cracking continued for about 10 ⁇ 1 minutes. The pre- and post-cracking temperatures were recorded. The 250 ml tube containing the lysed promastigotes was capped and stored at about 4 ⁇ 2 °C.
- the cracked cells were dispensed into a sterile 250 ml centrifuge bottle and centrifuged at about 3,100 ⁇ 200 rpm (1566 x g) in a Sorvall GSA rotor within a RC-5 Sorvall centrifuge at a time setting of about 30 ⁇ 1 minutes and at a temperature of about 4 ⁇ 2 °C.
- the bottle was removed and placed in a Class II Biohazard cabinet.
- the supernatant was poured of into a second sterilized 350 ml centrifuge tube and stored at about 4 ⁇ 2 °C.
- the pellet was then suspended with about 20 ml of Buffer B comprising, 0.001%) Tween 80 diluted with 0.9%o saline, and vortexed with vortex mixer. Ice was added into the cooling jacket of the microfluidizer as needed. When the regulator was at about 100 ⁇ 5 psi, the inlet tubing was inserted into the suspension and run through the microfluidizer in a continual fashion for about 10 minutes. The cracked cells were collected into a 250 ml centrifuge bottle containing the lysed promastigotes and placed on ice. The pre- and post-cracking temperatures were recorded. Then two 0.5 ml of the cracked cell samples were taken and stored at about -80 ⁇ 10 °C. On ice, the cracked cells and the supernatant were combined and mixed by swirling in the container.
- Buffer B comprising, 0.001%
- the post-cracked cells were immediately centrifuged at about 12,200 ⁇ 200 rpm (about 23,435 to about 25,062 x g) in a Sorval GSA rotor within a RC-5 Sorvall centrifuge for about 30 ⁇ 1 minutes at about 4 ⁇ 2 °C. Then the bottle was removed and placed in BSC, the supernatant was poured off into a sterile 250 ml graduated cylinder and the pellet in the 250 ml bottle was retained.
- samples were aseptically obtained and assayed for protein content by BCA, endotoxin content LAL (gel-clot), pH, sterility, HPLC, purity by SDS-PAGE, color and appearance.
- microfluidized lysate preparation was used in a skin test assay for detecting whether a subject had been exposed to a Leishmania parasite, such as L. tropica.
- a Leishmania parasite such as L. tropica.
- one of ordinary skill in the art may prepare a microfluidized preparation from more than one Leishmania parasite.
- the present invention also provides a multivalent microfluidized lysate preparation prepared from at least two different Leishmania parasites.
- the preparation may comprise the microfluidized lysate of E. tropica, L. mexicana, and L. guyanensis.
- the skin test assay of the present invention comprises administering to a subject an antigenic amount of a microfluidized lysate of the present invention.
- the subject is a mammal, more preferably, the subject is human.
- the microfluidized lysate preparation is administered intradermally, more preferably, the microfluidized lysate preparation is injected into the volar surface of the forearm of the subject. Induration is then measured.
- induration is measured at least once at about 24 to about 72 hours after the microfluidized lysate preparation was administered. More preferably, induration is measured at about 48 hours after induration as true delayed type hypersensitivity responses in humans are maximal at about 48 hours.
- an "antigenic amount” is an amount which provides a positive induration response in a subject known to be exposed to a leishmanial parasite. Antigenic amounts range from about 0.01 to about 1.0 ml, preferably about 0.05 to about 0.5 ml, more preferably about 0.1 ml. A positive response indicates previous exposure and sensitization to the antigen has occurred and is recalled, and an antigen specific inflammatory response takes place, thereby indicating that the subject was infected with or had been exposed to at least one Leishmania parasite. A positive response in humans is an induration of about 5 mm or more.
- the microfluidized lysate preparations of the present invention are safe and immunogenic. Therefore, the present invention also provides immunogenic compositions and vaccines comprising the microfluidized preparations of the present invention.
- the vaccine or immunogenic compositions of the present invention may be used in combination with an adjuvant, a pharmaceutically acceptable excipient, or both.
- the present invention also provides methods for immunizing subjects against diseases, infections, or disorders associated with Leishmania parasites, such as Leishmaniasis, all forms of leishmaniases, and diseases as Chagas Disease, and African trypanosomiasis were common crossreacting antigens with immunoprotective properties.
- the method of preparing the microfluidized lysate preparations as described herein maybe standardized and reproduced to prepare batches of microfluidized lysate preparations having substantially similar characteristics, such as potency and specificity, the microfluidized lysate preparations may be used to purify or screen for ligands which bind to leishmanial antigens or antibodies raised against the microfluidized lysate of the present invention with consistency.
- the microfluidized lysate preparations of the present invention are suitable for use as immunogens to raise anti-leishmanial antibodies.
- the antibodies may be prepared by immunizing a suitable subject, e.g., rabbit, goat, mouse or other mammal, with the microfluidized lysate of the present invention by methods standard in the art.
- the microfluidized lysate preparation may further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent.
- the present invention also provides antibody preparations made by immunizing a suitable subject with a microfluidized lysate preparation of the present invention.
- the antibodies produced by the subject may be isolated or purified by methods standard in the art.
- the antibodies raised against the microfluidized lysate of the present invention may be used to isolate leishmanial antigens by methods standard in the art, such as affinity chromatography or immunoprecipitation.
- the antibodies raised against the microfluidized lysate of the present invention may be used to diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable label or marker. Examples of detectable labels and markers include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
- suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
- suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
- suitable fluorescent materials include umbelhferone, fluorescem, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
- an example of a luminescent material includes luminol;
- bioluminescent materials include luciferase, luciferin, and i i l l c aequorin, and examples of suitable radioactive material include I, I, S or H.
- microfluidized lysate preparation, antibodies, or antigens of the present invention may be incorporated into a pharmaceutical composition suitable for administration.
- Such compositions typically comprise the microfluidized lysate preparation, antibodies, or antigens of the present invention and a pharmaceutically acceptable carrier.
- pharmaceutical compositions of the present invention comprise an antigenic amount of the microfluidized lysate preparation or antigen or a therapeutically effective amount of antibodies raised against the microfluidized lysate preparation, and an inert, pharmaceutically acceptable carrier or diluent.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
- the pharmaceutical compositions of the present invention include sterile saline comprising 0.4%> phenol.
- the antigenic activity of the microfluidized lysate of the present invention may be measured by any of the methods available to those skilled in the art, including in vitro and in vivo assays. Examples of suitable assays for activity measurements are provided herein. Properties of the microfluidized lysate, such as protein content, endotoxin content, pH, sterility, purity, and color, may be assessed, for example, by methods standard in the art. Other pharmacological methods may also be used to determine the efficacy of the microfluidized lysate as antigenic compositions.
- LSTA -Lg (BPR-2334-RS) was conducted as follows. A parasite specimen was obtained from an active dermal lesion from a human subject otherwise healthy with unremarkable medical history. The subject tested negative in screening with viral/STD panel (HIV, HTLV, CMV, HCV, HBV and syphilis). The subject's travel history was determined.
- FBS Fetal Bovine Serum
- FBS Type JJ The Fetal Bovine Serum (FBS) Type JJ, was mycoplasma and bovine virus tested, screened for bacteriophage, tested for endotoxin, tested for AVA, cell culture tested, heat-inactivated, and from a non BSE country (Gibco Life Technologies, Grand Island, NY; Fetal Bovine Serum, Qualified, Origin-United States, Catalogue Number 26140, Lot Number 1016982).
- the promastigotes cultured from this specimen, (strain WR2334) were determined by isoenzymes to be L. guyanensis. No known viral contaminants, such as LRV1-4, were detected in the promastigotes.
- a clonal line, WR2334 Clone D2 (WR2334-D2) was established through serial endpoint dilution and microscopic visualization of a single promastigote. This source seed stock of this clone was then expanded in culture, aliquoted and cryopreserved in liquid nitrogen. Sterility and morphology were determined by conventional methods.
- LSTA-Lg (BPR-377-00, Lot No. 0705) was manufactured under defined cGMP conditions from cryopreserved aliquots of WR2334-Clone D2, by culturing and expansion to roller bottles in appropriate medium.
- the cultured promastigotes were harvested by centrifugation, washed, suspended in cryopreservation medium, aliquoted, and stored in liquid nitrogen. Sterility and morphology were determined by conventional methods.
- LSTA-Lg (BPR-377-00, Lot No. 0705) was manufactured under defined cGMP conditions from cryopreserved aliquots of WR2334-Clone D2 Master Cell Bank, by culturing and expansion to roller bottles in appropriate medium. The cultured promastigotes were harvested by centrifugation, washed, suspended in cryopreservation medium, aliquoted, and stored in liquid nitrogen. Sterility and morphology were determined by conventional methods.
- BPR-383-00, Lot No. 0707 was produced. Specifically, bulk promastigotes were cultured in Schneider's Drosophila Medium (SDM), supplemented with 20%> fetal bovine serum (heat inactivated). The inoculum was initiated in flasks and when the culture set point was reached, it was transferred to roller bottles and expanded. Promastigotes were harvested by centrifugation when a sufficient quantity was been obtained. The culture was maintained in healthy, log-growth phase throughout the production run, including the time of harvest. Harvested promastigotes were centrifuged and washed 5 times.
- SDM Schneider's Drosophila Medium
- fetal bovine serum heat inactivated
- the pellets were reconstituted in sterile saline USP and manually filled in 5.0 mis aliquots at 109 promastigotes/ml.
- the vials were labeled, stored and frozen at -80 °C for subsequent production and purification steps. Sterility and morphology were determined by conventional methods.
- Lg (BPR-389-00, Lot No. 0716) was purified. Specifically, cryopreserved vials were thawed and processed through a microfluidizer (MFL#1). The material was centrifuged at 3,100 rpm for 30 minutes and the supernatant was saved. The pellet was resuspended and microfluidized again (MFL#2). The material was centrifuged at 12,200 rpm for 30 minutes and the two supernatants combined. The pooled supernatants were placed in a 0.22 micron sterile filter unit (500 ml) and filtered. The filtrate was then heat-treated at 90 °C for 15-20 minutes to inactivate parasite proteases.
- MFL#1 microfluidizer
- the final filtered and heat- treated bulk was formulated and the protein concentration adjusted to about 0.35 mg per ml.
- the lot was bottled and stored at 4 °C.
- the bulk material was tested for the following characteristics: Visual Inspection: Color, Appearance; Protein Content: micro- BCA (prior to phenol addition); Purity/Identity: SDS-PAGE, HPLC; and Quality: Sterility; Rabbit Pyrogen, Endotoxin (LAL), pH.
- the final product of L. guyanensis (WR2334-Clone D2) Leishmania Skin Test
- LSTA-Lg (BPR-390-00, Lot No. 0717) was placed in vials. Specifically, the formulated, bulk LSTA-Lg was aseptically filled in 1.0 ml aliquots into 10 ml Type I glass vials, closed with 20 mm rubber closures and stored at 4°C.
- a microfluidizer, Model #M- 11 OS was washed and autoclaved per the manufacturer's directions.
- the regulator was set and wet ice was put into the cooling jacket of the microfluidizer.
- the pump was primed by placing the inlet tubing into 500 ml of 0.001%) Tween 80 and 0.9% saline and then opening the air valve. With the regulator at 100 ⁇ 5 psi, the inlet tubing was inserted into the promastigotes suspension and run through the microfluidizer. Because the cracking pressure fluctuates, an average reading was taken. Cracked cells were collected into the reservoir containing the uncracked cells and cracking continued for 10 ⁇ 1 minutes. The pre- and post-cracking temperatures were recorded. The 250 ml tube containing the lysed promastigotes was capped and stored at 4 ⁇ 2 °C.
- the cracked cells were dispensed into a sterile 250 ml centrifuge bottle and centrifuged at 3,100 ⁇ 200 rpm (1566 x g) in a Sorvall GSA rotor within a RC-5 Sorvall centrifuge at a time setting of 30 ⁇ 1 minutes and at a temperature of 4 ⁇ 2 °C.
- the bottle was removed and placed in a Class U Biohazard cabinet.
- the supernatant was poured of into a second sterilized 350 ml centrifuge tube and stored at 4 ⁇ 2 °C.
- the pellet was then suspended with 20 ml of Buffer B, comprising 0.001% Tween 80 diluted with 0.9% saline, and vortexed with vortex mixer.
- Ice was added into the cooling jacket of the microfluidizer as needed.
- the inlet tubing was inserted into the suspension and run through the microfluidizer in a continual fashion for 10 minutes.
- Cracked cells were collected into a 250 ml centrifuge bottle containing the lysed promastigotes and placed on ice. The pre- and post-cracking temperatures were recorded. Then two 0.5 ml of the cracked cell samples were taken and stored at -80 ⁇ 10 °C. On ice the cracked cells and the supernatant were combined and mixed by swirling in the container.
- the post-cracked cells were immediately centrifuged at 12,200 ⁇ 200 rpm (23,435 - 25,062 x g) in a Sorval GSA rotor within a RC-5 Sorvall centrifuge for 30 ⁇ 1 minutes at 4 ⁇ 2 °C. Then the bottle was removed and placed in BSC, the supernatant was poured off into a sterile 250 ml graduated cylinder and the pellet in the 250 ml bottle was retained.
- the bulk clarified promastigotes lysate was tightly sealed and stored at 4 ⁇ 2 °C until treated with heat. 25%> glycerol was added to the bulk clarified promastigotes lysate to give a final concentration of 1% > and then mixed by swirling. The total weight of the in process bulk was determined. Then the bulk clarified promastigotes lysate was incubated for 30 ⁇ 2 minutes using a water bath at 93 ⁇ 2 °C. After heat treatment, the bulk was cooled at 4 ⁇ 2 °C. Aseptically two 0.5 ml aliquots were taken and retained at -80 ⁇ 10 °C. One 1.0 ml sample was taken for protein concentration testing by the Bio-Rad method (Bio-Rad Laboratories, Hercules, CA) and for SDS-PAGE.
- samples were aseptically obtained and assayed for protein content by BCA, endotoxin content LAL (gel-clot), pH, sterility, HPLC, purity by SDS-PAGE, color and appearance.
- FIG. 1 is a flow diagram of process for making the Leishmaniasis microfluidized lysate of the present invention.
- Example 3 Skin Test Antigen Assay in 10 Subjects [62] A microfluidized lysate preparation of L. tropica prepared according the Example
- the microfluidized lysate preparation further included Tween-80® and dextran.
- the subjects received four doses two weeks apart of 0.1 ml of the microfluidized lysate preparation in escalating concentrations.
- the first dose had 0.25 ⁇ g
- the second dose had 2.5 ⁇ g
- the third dose had 8.0 ⁇ g
- the fourth dose had 25.0 ⁇ g of total protein. 25.0 ⁇ g of the preparation was found to be safe in six of the 10 subjects.
- One subject developed clear rhinorrhea and nasal pruritus within minutes of receiving the first dose. Four hours later, transient urticaria at the test and control-diluent sites occurred.
- Phenol as a preservative was tested in 15 Leishmania na ⁇ ve human subjects and was found to be safe as a single injection at doses of 0.38 ⁇ g, 3.8 ⁇ g, and 38.0 ⁇ g.
- a subject is deemed to be clinically diagnosed with an active Leishmaniasis infection upon the demonstration of motile promastigotes in aspirate cultures or microscopic Leishmania amastigotes in samples obtained from lesions obtained from the subject.
- the parasite may be visualized by conventional methods.
- a subject is deemed to be clinically healed upon 100% reepitheliazation of the ulcer.
- Antigen 40 CFU/ml, MSTA®, Connaught Labs Inc. (Swiftwater, PM), and Candida albicans skin test antigen, Candin®, Allermed Laboratories, Inc. (San Diego, CA), before receiving the preparations.
- Subj ects who have a history of atopy, allergic reactions, or asthma will be excluded from the study including those who are allergic to phenol, pharmaceutical detergents or glycol. Also excluded are those subjects taking steroids, antihistamines, cimetidine, and immunosupressants, as well as those who had a splenectomy or have an active medical or psychiatric conditions that may increase the risks associated with participation in the study or interfere with the interpretation of study results. Pregnant or nursing subjects will be excluded. Subjects having active cutaneous Leishmaniasis with scars, i.e. possible re-infections and residivant Leishmaniasis will be excluded. Subjects having been immunized within 4 weeks prior to the start of the study will be excluded as well as those having anergy on delayed type hypersensitivity testing (less than about 5 mm of induration).
- Primary endpoints are the occurrence of local or systemic reactions to the skin or the occurrence of non-specific immune responses to the skin tests.
- the microfluidized lysate preparations are considered safe if there are no clinically significant local or systemic reactions in the healthy and healed subjects.
- the micro fluizided lysate preparations will also be considered safe if no severe reactions are determined in active leishmania subjects.
- Secondary endpoints are the size of the induration which accompanies the delayed type hypersensitivity response (potency); the percentage of subjects with Leishmaniasis in which the preparation induced a positive response about 5 mm or greater delayed type hypersensitivity reaction (sensitivity), the percent of healthy subjects in which the preparation fails to induce a positive delayed type hypersensitivity reaction (specificity).
- microfluidized lysate preparations are first tested in healthy subjects, followed by healed subjects, and followed by visceral or cutaneous subjects.
- the same subject is administered three different preparations, E. mexicana, L. tropica, and E. guyanensis, at a given concentration simultaneously.
- This study allows the direct comparison of the three preparations and reduces the number of subjects in the study.
- the study is a dose escalation study which tests three dose levels of the microfluidized lysate preparations. Three cohorts of 20 subjects per clinical group are used. The dose of each preparation escalates for each cohort.
- Intradermal injections of saline and a 1:100 dilution of the diluent are administered as controls concomitantly with the preparations.
- 20 healthy subjects (Cohort 1) are administered microfluidized lysate preparations having total protein concentrations of 5 ⁇ g (0.1 ml ID). If no clinically significant reaction is observed within two days after administration in Cohort 1, Cohort 2 is administered preparations having 15.0 ⁇ g total protein (0.1 ml ID). If no significant reaction is observed within two days after administration in Cohort 2, Cohort 3 is administered preparations having 30.0 ⁇ g total protein (0.1 ml ID). Each subject is followed for two days to assess local and systemic reactions.
- the controls are 0.1 ml saline and a 1:100 dilution of the microfluidized lysate preparation diluent comprising 0.001% Tween-80, 1% glycerol, 0.4%> phenol diluted with 0.9% saline stored at 4 ⁇ 2 °C.
- 0.1 ml of a microfluidized lysate preparation is injected intradermally into alcohol-cleansed volar surface of the forearm under the supervision of a physician who will have medication and equipment to treat anaphylaxis.
- the diameter of the induration, erythema, or both will be measured in millimeters at about 30 minutes after administration to detect immediate IgE hypersensitivity, and about 48 hours later to detect delayed type hypersensitivity by outlining the indurated border with a ballpoint pen and transferring to paper damped with 70%> ethanol for permanent record. The largest diameter and its perpendicular diameter are measured and averaged.
- the Sokal method maybe used. See Montenegro, J. (1926) Archives of Dermatology and Syphilology 13:187-194. The placement of each preparation and control for each subject are randomized and recorded. Skin test readers are unaware of the placements. Subjects are monitored closely.
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/031894 WO2003033533A1 (en) | 2001-10-12 | 2001-10-12 | Microfluidized leishmania antigen and methods of making and using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1436325A1 true EP1436325A1 (en) | 2004-07-14 |
Family
ID=21742903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01979743A Ceased EP1436325A1 (en) | 2001-10-12 | 2001-10-12 | Microfluidized leishmania antigen and methods of making and using thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1436325A1 (en) |
CA (1) | CA2463581A1 (en) |
WO (1) | WO2003033533A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL82740A0 (en) * | 1987-06-01 | 1987-12-20 | Yeda Res & Dev | Assay for leishmaniasis |
EP2284186A1 (en) * | 1997-02-12 | 2011-02-16 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
-
2001
- 2001-10-12 CA CA002463581A patent/CA2463581A1/en not_active Abandoned
- 2001-10-12 EP EP01979743A patent/EP1436325A1/en not_active Ceased
- 2001-10-12 WO PCT/US2001/031894 patent/WO2003033533A1/en not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO03033533A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003033533A1 (en) | 2003-04-24 |
CA2463581A1 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3165148B2 (en) | Diagnosis and treatment of insulin-dependent diabetes | |
US8425919B2 (en) | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis | |
CN102083853B (en) | Fusion proteins and their use in the diagnosis and treatment of leishmaniasis | |
US20130177584A1 (en) | Recombinant Polyprotein Vaccines For the Treatment and Diagnosis of Leishmaniasis | |
AU5103293A (en) | Immortalized cells and uses therefor | |
US4767622A (en) | Method and materials for development of immunological responses protective against malarial infection | |
US9068007B2 (en) | Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease | |
CA2462946C (en) | Recombinant p. falciparum merozoite protein-142 vaccine | |
US4596707A (en) | Babesia parasite antigen useful in vaccine and diagnostic reagent | |
WO2017205225A2 (en) | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections | |
JP2013508719A (en) | Diagnostic and therapeutic methods for rheumatic heart disease based on Group A Streptococcus markers | |
CZ295110B6 (en) | Novel peptides derived from human heat shock protein 60 for treatment of diabetes mellitus, pharmaceutical compositions containing such peptides, treatment methods and diagnostic kits | |
AU2003214591A1 (en) | Hsp70-derived peptides an uses thereof in the diagnosis and treatment of autoimmune diseases | |
CA2683888A1 (en) | Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease | |
US20030072714A1 (en) | Microfluidized leishmania lysate and methods of making and using thereof | |
US20180161416A1 (en) | Exosomes and their use as vaccine | |
TWI228419B (en) | Neospora vaccine | |
US20160158329A1 (en) | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis | |
WO2003033533A1 (en) | Microfluidized leishmania antigen and methods of making and using thereof | |
AU2002211673A1 (en) | Microfluidized leishmania antigen and methods of making and using thereof | |
Niu et al. | Expression of sheep pathogen Babesia sp. Xinjiang rhoptry-associated protein 1 and evaluation of its diagnostic potential by enzyme-linked immunosorbent assay | |
US4457915A (en) | Babesiosis vaccine prepared from soluble parasitic antigen factors isolated from disintegration of Babesia infected erythrocites | |
Woolridge et al. | Further studies with a complement fixation test for trachoma | |
WO2018087644A2 (en) | Immunogenic giant extracellular vesicles (vegs) of parasitic protozoa and methods for their induction and purification | |
RU2341288C1 (en) | MEDICINE FORMING CELLULAR IMMUNITY FOR MYCOBACTERIUM TUBERCULOSIS H37 Rv, METHOD OF PRODUCTION THEREOF (VERSIONS), RECOMBINANT STRAIN AND TUBERCULOSIS DIAGNOSTIC AGENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040510 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20041210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BALLOU, WILLIAM, R. Owner name: ECKELS, KENNETH, H. Owner name: ROWTON, EDGAR, D. Owner name: GROGL, MAX Owner name: STITELER, JOHN, M. Owner name: MAGILL, ALAN, J. Owner name: US ARMY MEDICAL RESEARCH & MATERIEL COMMAND |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: US ARMY MEDICAL RESEARCH & MATERIEL COMMAND |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20061228 |